Q3 2022 Results

Company overview Financial performance Cardiovascular Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Neuroscience Oncology Piqray® - PI3K-alpha inhibitor NCT04208178 EPIK-B2 (CBYL719G12301) Indication HER2+ adv breast cancer Phase 3 Phase Patients 548 Primary Outcome Measures Arms Intervention Progression-free survival (PFS) Alpelisib + trastuzumab + pertuzumab Trastuzumab + pertuzumab Patients with HER2-positive advanced breast cancer with a PIK3CA mutation Target Patients Read-out Milestone(s) 2025 Publication TBD 72 Investor Relations | Q3 2022 Results Piqray®-PI3K-alpha inhibitor References Abbreviations Other Indication Phase NCT04251533 EPIK-B3 (CBYL719H12301) Triple negative breast cancer Phase 3 Patients 566 Primary Progression-free Survival (PFS) for patients with PIK3CA mutant status Outcome Measures Arms Intervention Target Patients Alpelisib 300 mg + nab-paclitaxel 100 mg/m² Placebo nab-paclitaxel 100 mg/m² Patients with advanced triple negative breast cancer with either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) mutation or Phosphatase and Tensin Homolog Protein (PTEN) loss without PIK3CA mutation Read-out Milestone(s) Publication 2025 TBD NOVARTIS | Reimagining Medicine

View entire presentation